clinical trial · NCT06947083
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 39
MyelomaElranatamab
brief summary
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.
started
May 27, 2025
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Dec 3, 2025
official title
Phase II Study of Elranatamab as Maintenance Therapy Post Ciltacabtagene-autoleucel(Cilta-cel) in Patients With Clinical High Risk Relapsed Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol